Contact us : info@bioworlde.com
Home > Product > Antigen-Peptide
CYP19A1 (K243) Peptide BS2516P
Product NameCYP19A1 (K243) Peptide
Catalog No.BS2516P
ApplicationsBlocking
Swiss-ProtP11511
Product1 mg/ml in DI water.
Purification&PuritySynthetic peptide CYP19A1 (K243). (Note: the amino acid sequence is proprietary). The purity is > 98%.
Storage&StabilityStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
SpecificityThis peptide can be used with studies using BS2516 CYP19A1 (K243) pAb.
Browse similar products>>
Size Price
1mg $368
Add to cart My orders
Product Name :
CYP19A1 (K243) Peptide
Applications :
Blocking
Background :
P450 enzymes constitute a family of monooxygenase enzymes that are involved in the metabolism of a wide array of endogenous and xenobiotic compounds. P450 enzymes can be classified, based on their sequence similarities, into distinct subfamilies, which include CYP1A and CYP2A. Other P450 family members include CYP19, also designated aromatase (P450arom), which catalyzes the conversion of C19 steroids to estrogens in various tissues, including placenta, gonads, adipose tissue, skin and brain. CYP19 expression is controlled by hormonally regulated promoters in different tissues and increased aromatase activity is associated with familial gynecomastia. Also, a polymorphic allele of CYP19 (repeat (TTTA)12) is present in a majority of breast cancer patients.
Alternative Name :
Aromatase; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; CYP19A1; ARO1; CYAR; CYP19
Swiss-Prot :
P11511
Product :
1 mg/ml in DI water.
Purification&Purity :
Synthetic peptide CYP19A1 (K243). (Note: the amino acid sequence is proprietary). The purity is > 98%.
Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :
This peptide can be used with studies using BS2516 CYP19A1 (K243) pAb.
Blocking peptide available as BS2516PP
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER